LongevityNot approvedHHS draft policy (proposed, not final)Evidence tier: Human Observational

Epithalon

Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 29, 2026.

FDA status

Not approved

Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.

FDA primary source on file

Evidence tier

Human Observational. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 155 PubMed citations indexed.

Epithalon in the literature

Synthetic pineal tetrapeptide activating telomerase, modulating melatonin synthesis via AANAT/pCREB pathways, and epigenetically regulating gene expression.

What the literature studies

Telomerase Activation & Longevity

Evidence tier

Human Observational

Compounding record

HHS proposed 503A enforcement discretion (not final)

Confidence
3/5

Regulatory record

HHS proposed 503A enforcement discretion (not final). FDA substance context: Epitalon (Epithalon). Named in the proposed HHS 503A enforcement-discretion notice (Federal Register 2026-22192, October 2026). The policy is proposed, not final, and is not FDA approval. FDA's earlier record lists the nomination as withdrawn from Category 2 with potential significant safety risks. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.

Regulatory source checked October 29, 2026. This compounding label is separate from the approval line above.

FDA primary source 1 FDA primary source 2

human data limited to small Soviet-era observational studies.

Questions

Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.

Short answer

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide from the Khavinson pineal-peptide line that can induce telomerase activity in human cells in vitro; it is not FDA-approved, FDA lists it among withdrawn nominations with no identified human safety data for proposed routes, and adequate randomized human outcome trials of synthetic Epitalon are lacking.

What it is

Synthetic tetrapeptide AEDG (also spelled Epithalon / Epithalon), modeled on pineal peptide preparations (Epithalamin) studied by Khavinson and colleagues [R1].

Legal / FDA status (as of Oct 27 2026)

Not FDA-approved. FDA lists Epitalon under nominated-but-withdrawn bulk substances: compounded products may pose immunogenicity risk from aggregation/impurities; FDA "has not identified safety-related information regarding epitalon for the proposed route of administration" and therefore lacks sufficient information to know whether it would cause harm in humans [FDA-RISK]. Secondary reports place Epitalon among peptides that received a nonbinding July 2026 PCAC recommendation; that is not approval or automatic 503A listing [AJMC].

Human evidence

  • In vitro: Epithalon induced telomerase activity and telomere elongation in human somatic cells [R1]. A 2025 cell-line study reported telomere length increases via telomerase upregulation or ALT activity depending on cell type [R2].
  • Clinical literature often studies Epithalamin (a pineal peptide extract/preparation), not necessarily synthetic AEDG, with geriatric and ophthalmologic reports from Russian groups [R3]. These are not interchangeable without chemical identity confirmation.
  • No adequately powered, English-language randomized controlled trial establishing anti-aging, lifespan, or disease outcomes for synthetic Epitalon was identified.

Animal / lab evidence

Rodent geroprotective and chronobiologic studies in the Khavinson literature. Cell and animal findings are not clinical proof in people.

Risks and unknowns

FDA: no identified human safety package for proposed routes; immunogenicity/impurity concerns [FDA-RISK]. Theoretical concern whenever telomerase/ALT pathways are modulated, especially regarding neoplastic risk - not quantified in human Epitalon RCTs. Gray-market products unverified; name confusion with Epithalamin is common.

What's coming

Watch final FDA action on 503A listing after PCAC input, and the interim peptide compounding policy text [OIRA][AJMC].

Sources

  1. [R1] Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135:590-592. PMID 12937682
  2. [R2] (2025) Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. PMID 40908429
  3. [R3] Khavinson V, Anisimov V. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003. PMID 14523363 (Epithalamin/thymic preparations; not proof for synthetic AEDG alone)
  4. [FDA-RISK] FDA. Certain Bulk Drug Substances... (Epitalon entry). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  5. [AJMC] AJMC. FDA Panel Backs 6 Peptides for Compounding. Jul 31 2026. https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
  6. [OIRA] OIRA. Pending EO 12866 Review, RIN 0910-ZD94. https://www.reginfo.gov/public/do/eoDetails?rrid=1568964

Last checked 2026-10-27

Education only. Not medical advice. No dosing guidance. peptidex.ai does not sell peptides or link to sellers.